TY - JOUR
T1 - Cost-effectiveness of liver cancer screening in adults at high risk for liver cancer in the Republic of Korea
AU - Lee, Young Hwa
AU - Choi, Kui Son
AU - Jun, Jae Kwan
AU - Suh, Mina
AU - Lee, Hoo Yeon
AU - Kim, Youn Nam
AU - Nam, Chung Mo
AU - Park, Eun Cheol
AU - Cho, Woo Hyun
PY - 2014
Y1 - 2014
N2 - Purpose: This study was conducted in order to determine the most cost-effective strategy, in terms of interval and age range, for liver cancer screening in the high-risk population of Korea. Materials and Methods: A stochastic model was used to simulate the cost-effectiveness of liver cancer screening by combined ultrasonography and alpha-fetoprotein testing when varying both screening intervals and age ranges. The effectiveness of these screening strategies in the high-risk population was defined as the probability of detecting preclinical liver cancer, and cost was based on the direct cost of the screening and confirmative tests. Optimal cost-effectiveness was determined using the incremental cost-effectiveness ratio. Results: Among the 36 alternative strategies, one-year or two-year interval screening for men aged between 50 and 80 years, six-month or one-year interval screening for men aged between 40 and 80 years, and six-month interval screening for men aged between 30 and 80 years were identified as non-dominated strategies. For women, identified non-dominated strategies were: one-year interval screening between age 50 and 65 years, one-year or six-month interval screening between age 50 and 80 years, six-month interval screening between age 40 and 80 years, and six-month interval screening between age 30 and 80 years. Conclusion: In Korea, a one-year screening interval for men aged 50 to 80 years would be marginally cost-effective. Further studies should be conducted in order to evaluate effectiveness of liver cancer screening, and compare the cost effectiveness of different liver cancer screening programs with a final outcome indicator such as quality adjusted life-years or disability-adjusted life-years.
AB - Purpose: This study was conducted in order to determine the most cost-effective strategy, in terms of interval and age range, for liver cancer screening in the high-risk population of Korea. Materials and Methods: A stochastic model was used to simulate the cost-effectiveness of liver cancer screening by combined ultrasonography and alpha-fetoprotein testing when varying both screening intervals and age ranges. The effectiveness of these screening strategies in the high-risk population was defined as the probability of detecting preclinical liver cancer, and cost was based on the direct cost of the screening and confirmative tests. Optimal cost-effectiveness was determined using the incremental cost-effectiveness ratio. Results: Among the 36 alternative strategies, one-year or two-year interval screening for men aged between 50 and 80 years, six-month or one-year interval screening for men aged between 40 and 80 years, and six-month interval screening for men aged between 30 and 80 years were identified as non-dominated strategies. For women, identified non-dominated strategies were: one-year interval screening between age 50 and 65 years, one-year or six-month interval screening between age 50 and 80 years, six-month interval screening between age 40 and 80 years, and six-month interval screening between age 30 and 80 years. Conclusion: In Korea, a one-year screening interval for men aged 50 to 80 years would be marginally cost-effective. Further studies should be conducted in order to evaluate effectiveness of liver cancer screening, and compare the cost effectiveness of different liver cancer screening programs with a final outcome indicator such as quality adjusted life-years or disability-adjusted life-years.
UR - http://www.scopus.com/inward/record.url?scp=84905226815&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84905226815&partnerID=8YFLogxK
U2 - 10.4143/crt.2014.46.3.223
DO - 10.4143/crt.2014.46.3.223
M3 - Article
AN - SCOPUS:84905226815
SN - 1598-2998
VL - 46
SP - 223
EP - 233
JO - Cancer Research and Treatment
JF - Cancer Research and Treatment
IS - 3
ER -